BRAF and Pruritus: We present a case of a 64-year-old male with metastatic colorectal cancer who developed severe pruritus and widespread new skin lesions following treatment with encorafenib, a v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor, and panitumumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody.